| Authors: |
Menzies AM; aMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia., Long GV; aMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia., Kohn A; bOregon Health Sciences University, Division of Hematology/Medical Oncology, School of Medicine, Portland, OR, USA., Tawbi H; cUniversity of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology Houston, TX, USA., Webe J; dLaura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Flaherty K; eMassachusetts General Hospital, Massachusetts General Cancer Center, Boston, MA, USA., McArthur GA; fPeter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology University of Melbourne, Melbourne, VIC, Australia., Ascierto PA; gAzienda Universitaria Policlinico Federico II, Unit of Melanoma Cancer Immunotherapy and Innovative therapy, Naples, Italy., Pfluger Y; hAlexander Fleming Institute, Buenos Aires, Argentina., Lewis K; iUniversity of Colorado, Health Center, Medical Oncology, Denver, CO, USA., Tsai KK; jUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Hamid O; kThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA., Prenen H; lUniversity Hospital Antwerp, Oncology Department, Antwerp, Belgium., Fein L; hAlexander Fleming Institute, Buenos Aires, Argentina., Wang E; mPfizer, New York, NY, USA., Guenzel C; mPfizer, New York, NY, USA., Zhang F; mPfizer, New York, NY, USA., Kleh JF; aMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia.; mPfizer, New York, NY, USA., di Pietro A; nPfizer Srl, Milan, Italy., Davies MA; cUniversity of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology Houston, TX, USA. |
